Whilst several prospective studies have examined the incidence of endometrial cancer after risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 and BRCA2 pathogenic variant carriers compared with the general population, they have failed to consider the impact of the procedure on the rate of endometrial cancer within this specific population [12,13]. This evidence concerns the gene BRCA2 and endometrial cancer.